vs
Side-by-side financial comparison of Sachem Capital Corp. (SACH) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.0M, roughly 1.1× Sachem Capital Corp.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 8.3%, a 67.4% gap on every dollar of revenue.
Sachem Capital Corp.SACHEarnings & Financial Report
Sachem Head Capital Management is an American value-oriented investment management firm based in New York City, managed by Scott Ferguson.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
SACH vs XLO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.0M | $13.7M |
| Net Profit | $997.0K | $10.4M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | -86.5% |
| Net Margin | 8.3% | 75.7% |
| Revenue YoY | -18.8% | — |
| Net Profit YoY | 119.7% | 179.1% |
| EPS (diluted) | $0.00 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.7M | ||
| Q3 25 | $12.0M | $19.1M | ||
| Q2 25 | $10.8M | $8.1M | ||
| Q1 25 | $11.4M | $2.9M | ||
| Q4 24 | $10.8M | — | ||
| Q3 24 | $14.8M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $16.8M | — |
| Q4 25 | — | $10.4M | ||
| Q3 25 | $997.0K | $-16.3M | ||
| Q2 25 | $1.9M | $-15.8M | ||
| Q1 25 | $904.0K | $-13.3M | ||
| Q4 24 | $-36.1M | — | ||
| Q3 24 | $-5.1M | — | ||
| Q2 24 | $-3.1M | — | ||
| Q1 24 | $4.7M | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | -3.1% | -10.1% | ||
| Q2 25 | 9.9% | -177.7% | ||
| Q1 25 | 9.0% | -472.7% | ||
| Q4 24 | -131.1% | — | ||
| Q3 24 | -32.6% | — | ||
| Q2 24 | -20.6% | — | ||
| Q1 24 | 25.4% | — |
| Q4 25 | — | 75.7% | ||
| Q3 25 | 8.3% | -85.4% | ||
| Q2 25 | 17.5% | -196.0% | ||
| Q1 25 | 7.9% | -452.7% | ||
| Q4 24 | -335.6% | — | ||
| Q3 24 | -34.2% | — | ||
| Q2 24 | -20.2% | — | ||
| Q1 24 | 27.8% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | $0.00 | $-0.11 | ||
| Q2 25 | $0.02 | $-0.16 | ||
| Q1 25 | $0.00 | $-0.18 | ||
| Q4 24 | $-0.79 | — | ||
| Q3 24 | $-0.13 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.6M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $175.6M | $35.3M |
| Total Assets | $484.4M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | $12.6M | $103.8M | ||
| Q2 25 | $23.5M | $121.6M | ||
| Q1 25 | $25.8M | $89.1M | ||
| Q4 24 | $19.6M | — | ||
| Q3 24 | $7.4M | — | ||
| Q2 24 | $12.4M | — | ||
| Q1 24 | $56.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $230.2M | — | ||
| Q4 24 | $230.2M | — | ||
| Q3 24 | $264.7M | — | ||
| Q2 24 | $264.7M | — | ||
| Q1 24 | $288.4M | — |
| Q4 25 | — | $35.3M | ||
| Q3 25 | $175.6M | $-8.1M | ||
| Q2 25 | $177.9M | $7.1M | ||
| Q1 25 | $179.3M | $10.7M | ||
| Q4 24 | $181.7M | — | ||
| Q3 24 | $220.6M | — | ||
| Q2 24 | $230.2M | — | ||
| Q1 24 | $237.4M | — |
| Q4 25 | — | $154.7M | ||
| Q3 25 | $484.4M | $133.7M | ||
| Q2 25 | $501.8M | $133.8M | ||
| Q1 25 | $491.4M | $103.7M | ||
| Q4 24 | $492.0M | — | ||
| Q3 24 | $555.5M | — | ||
| Q2 24 | $586.3M | — | ||
| Q1 24 | $626.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.28× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.15× | — | ||
| Q1 24 | 1.21× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.9M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | 4.95× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.0M | ||
| Q3 25 | $4.9M | $-17.5M | ||
| Q2 25 | $501.0K | $-14.5M | ||
| Q1 25 | $191.0K | $29.0M | ||
| Q4 24 | $12.9M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $7.0M | — | ||
| Q1 24 | $4.2M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | 4.95× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
